Deep Track Capital
Latest statistics and disclosures from Deep Track Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SWTX, AMGN, APGE, INSM, DYN, and represent 21.23% of Deep Track Capital's stock portfolio.
- Added to shares of these 10 stocks: AMGN (+$156M), ALNY (+$124M), DYN (+$73M), MNMD (+$63M), APLS (+$59M), NTLA (+$54M), KYMR (+$51M), IVVD (+$49M), FATE (+$41M), ENGN (+$38M).
- Started 19 new stock positions in ENGN, MRSN, RGLS, ALNY, MGX, PRME, NMRA, RARE, APLS, ALEC. FATE, ANRO, KYMR, MNMD, IVVD, CYBN, COGT, AMGN, PYXS.
- Reduced shares in these 10 stocks: CYTK (-$137M), Ambrx Biopharma (-$53M), SRPT (-$48M), RAPT (-$45M), ACLX (-$40M), ANAB (-$34M), Orchard Therapeutics (-$34M), SWTX (-$29M), SYRE (-$28M), EWTX (-$28M).
- Sold out of its positions in AGIO, ACLX, CYTK, EWTX, Ambrx Biopharma, Orchard Therapeutics, PTGX, RAPT, SRPT, GHRS. JAZZ, PRTA.
- Deep Track Capital was a net buyer of stock by $349M.
- Deep Track Capital has $3.5B in assets under management (AUM), dropping by 16.59%.
- Central Index Key (CIK): 0001856083
Tip: Access up to 7 years of quarterly data
Positions held by Deep Track Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Deep Track Capital
Deep Track Capital holds 65 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Springworks Therapeutics (SWTX) | 4.9 | $171M | -14% | 3.5M | 49.22 |
|
| Amgen (AMGN) | 4.5 | $156M | NEW | 550k | 284.32 |
|
| Apogee Therapeutics (APGE) | 4.4 | $154M | 2.3M | 66.45 |
|
|
| Insmed Com Par $.01 (INSM) | 3.7 | $130M | -10% | 4.8M | 27.13 |
|
| Dyne Therapeutics (DYN) | 3.7 | $129M | +127% | 4.6M | 28.39 |
|
| Alnylam Pharmaceuticals (ALNY) | 3.6 | $124M | NEW | 832k | 149.45 |
|
| Guardant Health (GH) | 3.5 | $124M | +20% | 6.0M | 20.63 |
|
| Argenx Se Sponsored Adr (ARGX) | 3.4 | $118M | 300k | 393.72 |
|
|
| Intra Cellular Therapies Put Option (ITCI) | 3.3 | $116M | -16% | 1.7M | 69.20 |
|
| Intellia Therapeutics (NTLA) | 3.3 | $116M | +87% | 4.2M | 27.51 |
|
| Ocular Therapeutix (OCUL) | 3.3 | $116M | +37% | 13M | 9.10 |
|
| Dynavax Technologies Corp Com New (DVAX) | 3.2 | $113M | +28% | 9.1M | 12.41 |
|
| Axsome Therapeutics (AXSM) | 3.0 | $104M | +30% | 1.3M | 79.80 |
|
| Geron Corporation (GERN) | 2.9 | $101M | +3% | 31M | 3.30 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 2.8 | $97M | +28% | 15M | 6.38 |
|
| 4d Molecular Therapeutics In (FDMT) | 2.8 | $97M | +32% | 3.0M | 31.86 |
|
| Alkermes SHS (ALKS) | 2.7 | $95M | -12% | 3.5M | 27.07 |
|
| Bicycle Therapeutics Sponsored Ads (BCYC) | 2.5 | $87M | 3.5M | 24.90 |
|
|
| Pliant Therapeutics (PLRX) | 2.5 | $86M | 5.8M | 14.90 |
|
|
| Mind Medicine Mindmed Com New (MNMD) | 1.8 | $63M | NEW | 6.7M | 9.40 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.8 | $62M | 4.3M | 14.30 |
|
|
| Miragen Therapeutics (VRDN) | 1.7 | $61M | -4% | 3.5M | 17.51 |
|
| Ionis Pharmaceuticals (IONS) | 1.7 | $60M | +9% | 1.4M | 43.35 |
|
| Apellis Pharmaceuticals (APLS) | 1.7 | $59M | NEW | 1.0M | 58.78 |
|
| Biosante Pharmaceuticals (ANIP) | 1.6 | $57M | +37% | 822k | 69.13 |
|
| Travere Therapeutics (TVTX) | 1.6 | $57M | 7.4M | 7.71 |
|
|
| Verona Pharma Sponsored Ads (VRNA) | 1.5 | $51M | 3.2M | 16.09 |
|
|
| Kymera Therapeutics (KYMR) | 1.5 | $51M | NEW | 1.3M | 40.20 |
|
| Adagio Therapeutics (IVVD) | 1.4 | $49M | NEW | 11M | 4.44 |
|
| Spyre Therapeutics Com New (SYRE) | 1.3 | $46M | -37% | 1.2M | 37.93 |
|
| Nurix Therapeutics (NRIX) | 1.3 | $44M | 3.0M | 14.70 |
|
|
| Hillevax (HLVX) | 1.2 | $43M | -11% | 2.6M | 16.63 |
|
| Editas Medicine (EDIT) | 1.2 | $41M | 5.5M | 7.42 |
|
|
| Fate Therapeutics (FATE) | 1.2 | $41M | NEW | 5.6M | 7.34 |
|
| Terns Pharmaceuticals (TERN) | 1.1 | $40M | 6.1M | 6.56 |
|
|
| Engene Holdings (ENGN) | 1.1 | $38M | NEW | 2.3M | 16.95 |
|
| Tourmaline Bio (TRML) | 1.0 | $37M | -12% | 1.6M | 22.90 |
|
| Olema Pharmaceuticals (OLMA) | 1.0 | $37M | +67% | 3.2M | 11.32 |
|
| Silence Therapeutics Ads (SLN) | 1.0 | $36M | -15% | 1.6M | 21.60 |
|
| Pacific Biosciences of California (PACB) | 0.8 | $26M | 7.0M | 3.75 |
|
|
| Cybin Ord (CYBN) | 0.7 | $24M | NEW | 58M | 0.41 |
|
| Alector (ALEC) | 0.6 | $23M | NEW | 3.8M | 6.02 |
|
| Nuvalent Inc-a (NUVL) | 0.6 | $21M | -38% | 275k | 75.09 |
|
| Agenus Com New | 0.5 | $18M | 32M | 0.58 |
|
|
| Pyxis Oncology Common Stock (PYXS) | 0.5 | $18M | NEW | 4.2M | 4.26 |
|
| Nektar Therapeutics (NKTR) | 0.5 | $17M | 18M | 0.93 |
|
|
| Immunovant (IMVT) | 0.5 | $16M | -50% | 493k | 32.31 |
|
| Neumora Therapeutics (NMRA) | 0.4 | $14M | NEW | 1.0M | 13.75 |
|
| Repare Therapeutics Ord (RPTX) | 0.4 | $13M | -10% | 2.7M | 4.71 |
|
| Scholar Rock Hldg Corp (SRRK) | 0.3 | $12M | -32% | 680k | 17.76 |
|
| Anaptysbio Inc Common (ANAB) | 0.3 | $12M | -74% | 530k | 22.52 |
|
| Regulus Therapeutics (RGLS) | 0.3 | $9.4M | NEW | 3.3M | 2.88 |
|
| Alto Neuroscience Com Shs (ANRO) | 0.3 | $9.2M | NEW | 600k | 15.35 |
|
| Ultragenyx Pharmaceutical (RARE) | 0.2 | $7.8M | NEW | 168k | 46.69 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.2 | $6.5M | 2.5M | 2.57 |
|
|
| Allakos (ALLK) | 0.2 | $6.3M | +99% | 5.0M | 1.26 |
|
| Aligos Therapeutics (ALGS) | 0.2 | $6.0M | 6.1M | 0.98 |
|
|
| Relmada Therapeutics (RLMD) | 0.2 | $5.8M | -39% | 1.2M | 4.65 |
|
| Vigil Neuroscience (VIGL) | 0.2 | $5.4M | 1.6M | 3.41 |
|
|
| Metagenomi (MGX) | 0.1 | $4.9M | NEW | 466k | 10.55 |
|
| Syros Pharmaceuticals Com New (SYRS) | 0.1 | $4.4M | 829k | 5.35 |
|
|
| Mersana Therapeutics (MRSN) | 0.1 | $2.6M | NEW | 580k | 4.48 |
|
| Prime Medicine (PRME) | 0.1 | $2.1M | NEW | 304k | 7.00 |
|
| Cogent Biosciences (COGT) | 0.1 | $2.1M | NEW | 316k | 6.72 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.0 | $1.7M | -86% | 40k | 42.86 |
|
Past Filings by Deep Track Capital
SEC 13F filings are viewable for Deep Track Capital going back to 2021
- Deep Track Capital 2024 Q1 filed May 15, 2024
- Deep Track Capital 2023 Q4 filed Feb. 14, 2024
- Deep Track Capital 2023 Q3 filed Nov. 14, 2023
- Deep Track Capital 2023 Q2 restated filed Sept. 6, 2023
- Deep Track Capital 2023 Q2 filed Aug. 14, 2023
- Deep Track Capital 2023 Q1 filed May 15, 2023
- Deep Track Capital 2022 Q4 filed Feb. 14, 2023
- Deep Track Capital 2022 Q3 filed Nov. 14, 2022
- Deep Track Capital 2022 Q2 filed Aug. 12, 2022
- Deep Track Capital 2022 Q1 filed May 16, 2022
- Deep Track Capital 2021 Q4 filed Feb. 14, 2022